Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	396.3	251.1	262.9	340.8	187.1	115.5
Short-Term Investments	814.3	780.5	726.4	370.5	613.9	558.2
Cash & Cash Equivalents	1,211	1,032	989.3	711.3	801	673.7
Cash Growth	35.32%	4.28%	39.08%	-11.20%	18.90%	2.64%
Receivables	450.7	439.3	350	185.5	157.1	126.6
Inventory	37.2	38.3	35.1	30.5	28	17.3
Other Current Assets	100.5	97.8	79.1	45.5	30.1	13.4
Total Current Assets	1,799	1,607	1,454	972.8	1,016	831
Property, Plant & Equipment	346.1	347.3	145.6	155.8	127.4	116.2
Long-Term Investments	863.9	849.4	401.5	624.4	265.3	355.6
Goodwill and Intangibles	34.3	35.5	37.2	0	0	0
Other Long-Term Assets	429.1	412.2	330.9	319.5	325.8	3.2
Total Long-Term Assets	1,673	1,644	915.2	1,100	718.5	475
Total Assets	3,472	3,251	2,369	2,073	1,735	1,306
Accounts Payable	417.2	448.8	347.6	225.8	168.7	141.3
Current Debt	259	170.1	169.4	0	0	408.8
Other Current Liabilities	36.7	35.9	20.7	20	17.8	15.2
Total Current Liabilities	712.9	654.8	537.7	245.8	186.5	565.3
Long-Term Debt	252.9	258.3	93.5	440.4	412.3	86.7
Other Long-Term Liabilities	120.5	106.3	29.7	12.3	9.7	17.1
Total Long-Term Liabilities	373.4	364.6	123.2	452.7	422	103.8
Total Liabilities	1,086	1,019	660.9	698.5	608.5	669.1
Total Debt	511.9	428.4	262.9	440.4	412.3	495.5
Debt Growth	96.96%	62.95%	-40.30%	6.82%	-16.79%	27.54%
Retained Earnings	-113.7	-157.1	-406.8	-635.8	-725.4	-1,132.7
Comprehensive Income	3.3	7	-7.9	-1.7	1.8	1.4
Shareholders' Equity	2,386	2,232	1,708	1,374	1,126	636.9
Net Cash / Debt	698.7	603.2	726.4	270.9	388.7	178.2
Net Cash / Debt Growth	10.08%	-16.96%	168.14%	-30.31%	118.13%	-33.48%
Net Cash Per Share	6.74	5.97	7.34	2.77	3.97	1.86
Working Capital	1,086	952.2	915.8	727	829.7	265.7
Book Value Per Share	23.91	22.84	17.83	14.52	12.10	6.95

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).